Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Chemoproteomic discovery and characterization of covalent ligands for the oncoprotein CIP2A, a unique vulnerability in BRCA1/2-deficient cancers

Award Number: F32CA284727
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Chemoproteomic discovery and characterization of covalent ligands for the oncoprotein CIP2A, a unique vulnerability in BRCA1/2-deficient cancers - Loss-of-function BRCA1/2 mutations lead to defective homologous recombination (HR) activity, a frontline DNA damage repair pathway that accurately addresses double-strand breaks. In the absence of sufficient HR activity, BRCA1/2-deficient cancers are suggested to activate a non-canonical DNA maintenance mechanism dependent on the oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A). CIP2A colocalizes with the genome stability factor TOPBP1 at sites of DNA damage during mitosis. This complex is suggested to physically tether fragmented chromosomes and centromere-bearing counterparts to ensure proper division and cancer cell survival. After mitosis, chromosome fragments can undergo chromothripsis, a large- scale error-prone genomic rearrangement. Chromothriptic fragments also rely on CIP2A for proper division in the next cell cycle to ultimately potentiate oncogenesis. CIP2A knockdown is lethal in BRCA1/2-deficient cancers but does not harm HR-proficient cells, indicating CIP2A to be a unique therapeutic vulnerability. However, a bonafide CIP2A inhibitor has not yet been produced via standard drug discovery efforts and may require innovative strategies. Recent chemoproteomic analyses identified nucleophilic cysteine residues in CIP2A that can be covalently labeled (“liganded”) with electrophiles. While lead fragments provide starting points for further development, these scaffolds also non-selectively engage other proteins. Furthermore, the functional consequences of labeling CIP2A are unknown. The proposal will therefore achieve chemical inhibition of CIP2A using covalent degraders (e.g., PROTAC) and focuses on the following aims: (1) Identify potent and selective covalent ligands for CIP2A. (2) Develop heterobifunctional probes and evaluate proximity-dependent degradation of CIP2A. (3) Analyze chemical inhibition of CIP2A in BRCA1/2-deficient cells. Encouragingly, preliminary data indicate the proposed ligands label CIP2A in both cellular and in vitro settings. Building on these results, the first aim will synthesize a focused probe collection based on computational guidance and then assess target engagement using a state-of-the-art chemoproteomic workflow. In the second aim, selective ligands will be converted into heterobifunctional degraders and characterized for CIP2A degradation in BRCA1/2-deficient cells. The third aim will then evaluate the cellular activity of covalent degraders by tracking phenotypes indicative of CIP2A inhibition and defective mitosis. This proposal will provide valuable chemical tools to probe CIP2A function and lay the foundation for therapeutics to treat BRCA1/2-deficient cancers. During this fellowship, I am grateful to be mentored by multiple professors from the Rockefeller University: Tarun Kapoor, my advisor, a master in chemical probe design and cell division biology; Jiankun Lyu, an expert in computational chemistry; Ekaterina Vinogradova, a leader in chemoproteomics. Their mentorship will be supplemented with additional training both within Rockefeller and in the broader academic community. This fellowship represents an essential step towards my goal of performing independent research at the interface of chemical and cancer biology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $81,580 )
2026	2026	ROCKEFELLER UNIVERSITY	1230 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	000	3	4/6/2026	NON-COMPETING CONTINUATION	$81,580
														Subtotal = $81,580

Issue Date FY: 2025 ( Subtotal = $78,040 )
2025	2025	ROCKEFELLER UNIVERSITY	1230 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	001	2	6/4/2025	NON-COMPETING CONTINUATION	$1,284
2025	2025	ROCKEFELLER UNIVERSITY	1230 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	000	2	3/11/2025	NON-COMPETING CONTINUATION	$76,756
														Subtotal = $78,040

Issue Date FY: 2024 ( Subtotal = $74,284 )
2024	2024	ROCKEFELLER UNIVERSITY	1230 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	001	1	3/18/2024	NEW	$0
2024	2024	ROCKEFELLER UNIVERSITY	1230 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	000	1	3/18/2024	NEW	$69,500
2024	2024	ROCKEFELLER UNIVERSITY	1230 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	002	1	5/7/2024	NEW	$4,784
														Subtotal = $74,284

Grand Total All Awards = $233,904

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Chemoproteomic discovery and characterization of covalent ligands for the oncoprotein CIP2A, a unique vulnerability in BRCA1/2-deficient cancers

Award Number: F32CA284727

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer